1. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss
   Phuong Tran et al, 2018, International Journal of Molecular Medicine CrossRef
2. Extracellular Vesicles from Human Adipose Tissue-Derived Mesenchymal Stem Cells Suppress RANKL-Induced Osteoclast Differentiation via miR122-5p
   Joo-Hee Choi et al, 2024, Biochemical Genetics CrossRef
3. MiR-143 Inhibits Osteoclastogenesis by Targeting RANK and NF-κB and MAPK Signaling Pathways
   Xianfeng He et al, 2020, Current Molecular Pharmacology CrossRef
4. Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway
   Hong-Qing Niu et al, 2018, International Immunopharmacology CrossRef
5. Extracellular Signal-Regulated Kinases Play Essential but Contrasting Roles in Osteoclast Differentiation
   Chaekyun Kim, 2023, International Journal of Molecular Sciences CrossRef
6. Dual actions of osteoclastic-inhibition and osteogenic-stimulation through strontium-releasing bioactive nanoscale cement imply biomaterial-enabled osteoporosis therapy
   Na-Hyun Lee et al, 2021, Biomaterials CrossRef
7. The effects of VEGF-centered biomimetic delivery of growth factors on bone regeneration
   Ho Yong Kim et al, 2021, Biomaterials Science CrossRef